Literature DB >> 22321894

Prediction of HIV-1 protease/inhibitor affinity using RosettaLigand.

Gordon Lemmon1, Kristian Kaufmann, Jens Meiler.   

Abstract

Predicting HIV-1 protease/inhibitor binding affinity as the difference between the free energy of the inhibitor bound and unbound state remains difficult as the unbound state exists as an ensemble of conformations with various degrees of flap opening. We improve computational prediction of protease/inhibitor affinity by invoking the hypothesis that the free energy of the unbound state while difficult to predict is less sensitive to mutation. Thereby the HIV-1 protease/inhibitor binding affinity can be approximated with the free energy of the bound state alone. Bound state free energy can be predicted from comparative models of HIV-1 protease mutant/inhibitor complexes. Absolute binding energies are predicted with R = 0.71 and SE = 5.91 kJ/mol. Changes in binding free energy upon mutation can be predicted with R = 0.85 and SE = 4.49 kJ/mol. Resistance mutations that lower inhibitor binding affinity can thereby be recognized early in HIV-1 protease inhibitor development.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321894      PMCID: PMC3342459          DOI: 10.1111/j.1747-0285.2012.01356.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  30 in total

1.  Effective energy function for proteins in solution.

Authors:  T Lazaridis; M Karplus
Journal:  Proteins       Date:  1999-05-01

2.  Improved recognition of native-like protein structures using a combination of sequence-dependent and sequence-independent features of proteins.

Authors:  K T Simons; I Ruczinski; C Kooperberg; B A Fox; C Bystroff; D Baker
Journal:  Proteins       Date:  1999-01-01

3.  Toward high-resolution de novo structure prediction for small proteins.

Authors:  Philip Bradley; Kira M S Misura; David Baker
Journal:  Science       Date:  2005-09-16       Impact factor: 47.728

4.  HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.

Authors:  Soo-Yon Rhee; W Jeffrey Fessel; Andrew R Zolopa; Leo Hurley; Tommy Liu; Jonathan Taylor; Dong Phuong Nguyen; Sally Slome; Daniel Klein; Michael Horberg; Jason Flamm; Stephen Follansbee; Jonathan M Schapiro; Robert W Shafer
Journal:  J Infect Dis       Date:  2005-07-05       Impact factor: 5.226

Review 5.  Protein-ligand docking: current status and future challenges.

Authors:  Sérgio Filipe Sousa; Pedro Alexandrino Fernandes; Maria João Ramos
Journal:  Proteins       Date:  2006-10-01

6.  HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations.

Authors:  Viktor Hornak; Asim Okur; Robert C Rizzo; Carlos Simmerling
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

7.  ROSETTALIGAND: protein-small molecule docking with full side-chain flexibility.

Authors:  Jens Meiler; David Baker
Journal:  Proteins       Date:  2006-11-15

Review 8.  HIV-1 protease: structure, dynamics, and inhibition.

Authors:  John M Louis; Rieko Ishima; Dennis A Torchia; Irene T Weber
Journal:  Adv Pharmacol       Date:  2007

9.  Interflap distances in HIV-1 protease determined by pulsed EPR measurements.

Authors:  Luis Galiano; Marco Bonora; Gail E Fanucci
Journal:  J Am Chem Soc       Date:  2007-08-17       Impact factor: 15.419

Review 10.  Dynamic personalities of proteins.

Authors:  Katherine Henzler-Wildman; Dorothee Kern
Journal:  Nature       Date:  2007-12-13       Impact factor: 49.962

View more
  9 in total

1.  Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.

Authors:  Jordan R Willis; Gopal Sapparapu; Sasha Murrell; Jean-Philippe Julien; Vidisha Singh; Hannah G King; Yan Xia; Jennifer A Pickens; Celia C LaBranche; James C Slaughter; David C Montefiori; Ian A Wilson; Jens Meiler; James E Crowe
Journal:  J Clin Invest       Date:  2015-05-18       Impact factor: 14.808

2.  Web-accessible molecular modeling with Rosetta: The Rosetta Online Server that Includes Everyone (ROSIE).

Authors:  Rocco Moretti; Sergey Lyskov; Rhiju Das; Jens Meiler; Jeffrey J Gray
Journal:  Protein Sci       Date:  2017-10-27       Impact factor: 6.725

3.  Small-molecule ligand docking into comparative models with Rosetta.

Authors:  Steven A Combs; Samuel L Deluca; Stephanie H Deluca; Gordon H Lemmon; David P Nannemann; Elizabeth D Nguyen; Jordan R Willis; Jonathan H Sheehan; Jens Meiler
Journal:  Nat Protoc       Date:  2013-06-06       Impact factor: 13.491

4.  Introduction to the BioChemical Library (BCL): An Application-Based Open-Source Toolkit for Integrated Cheminformatics and Machine Learning in Computer-Aided Drug Discovery.

Authors:  Benjamin P Brown; Oanh Vu; Alexander R Geanes; Sandeepkumar Kothiwale; Mariusz Butkiewicz; Edward W Lowe; Ralf Mueller; Richard Pape; Jeffrey Mendenhall; Jens Meiler
Journal:  Front Pharmacol       Date:  2022-02-21       Impact factor: 5.810

5.  PlaceWaters: Real-time, explicit interface water sampling during Rosetta ligand docking.

Authors:  Shannon T Smith; Laura Shub; Jens Meiler
Journal:  PLoS One       Date:  2022-05-31       Impact factor: 3.752

6.  Fully Flexible Docking of Medium Sized Ligand Libraries with RosettaLigand.

Authors:  Samuel DeLuca; Karen Khar; Jens Meiler
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

7.  In silico prediction of mutant HIV-1 proteases cleaving a target sequence.

Authors:  Jan H Jensen; Martin Willemoës; Jakob R Winther; Luca De Vico
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

Review 8.  Protocols for Molecular Modeling with Rosetta3 and RosettaScripts.

Authors:  Brian J Bender; Alberto Cisneros; Amanda M Duran; Jessica A Finn; Darwin Fu; Alyssa D Lokits; Benjamin K Mueller; Amandeep K Sangha; Marion F Sauer; Alexander M Sevy; Gregory Sliwoski; Jonathan H Sheehan; Frank DiMaio; Jens Meiler; Rocco Moretti
Journal:  Biochemistry       Date:  2016-08-16       Impact factor: 3.162

9.  Human germline antibody gene segments encode polyspecific antibodies.

Authors:  Jordan R Willis; Bryan S Briney; Samuel L DeLuca; James E Crowe; Jens Meiler
Journal:  PLoS Comput Biol       Date:  2013-04-25       Impact factor: 4.475

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.